<DOC>
	<DOCNO>NCT02187003</DOCNO>
	<brief_summary>This clinical study evaluate efficacy safety rivipansel ( GMI-1070 ) treat subject sickle cell disease ( SCD ) 6 year age old experience pain crisis necessitate hospitalization .</brief_summary>
	<brief_title>Efficacy Safety Rivipansel ( GMI-1070 ) Treatment Vaso-Occlusive Crisis Hospitalized Subjects With Sickle Cell Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>At least 6 year age . Documented diagnosis sickle cell disease . Diagnosis vasoocclusive crisis necessitate admission hospital treatment include IV opioids . Able receive first dose study drug within 24 hour administration IV opioids . Serious systemic infection Acute Chest Syndrome Serious concomitant medical problem ( example , stroke ) SCD pain atypical VOC Severe renal hepatic impairment Chronic pain rather presentation acute VOC</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sickle Cell Anemia</keyword>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Sickle Cell Disorders</keyword>
	<keyword>pain crisis</keyword>
	<keyword>vaso-occlusive crisis</keyword>
	<keyword>rivipansel</keyword>
	<keyword>GMI-1070</keyword>
	<keyword>selectin inhibitor</keyword>
	<keyword>SCD</keyword>
	<keyword>VOC</keyword>
</DOC>